<DOC>
	<DOCNO>NCT00005023</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response tumor cell . Colony-stimulating factor sargramostim increase number immune cell find bone marrow peripheral blood . PURPOSE : Phase I trial study effectiveness vaccine therapy plus sargramostim treating patient stage III stage IV cancer .</brief_summary>
	<brief_title>Vaccine Therapy Plus Sargramostim Treating Patients With Stage III Stage IV Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety serial intradermal subcutaneous vaccination HER-2 derive p369-377 peptide incorporate polylactide-co-glycolide ( PLG ) microspheres adjuvant sargramostim ( GM-CSF ) patient stage III IV HER-2 express cancer . II . Determine whether cytotoxic T lymphocytes ( CTL ) specific HER-2 protein elicit patient HLA-A2 immunization regimen . III . Determine route immunization , intradermal subcutaneous , effective generate HER-2 specific CTL patient regimen . IV . Determine extent escalate dose PLG peptide affect immune response patient regimen . OUTLINE : Patients undergo leukapheresis prior study final vaccination . Patients sequentially enter one three treatment arm : Arm I : Patients receive intradermal vaccination HER-2 derive p369-377 peptide incorporate polylactide-co-glycolide ( PLG ) microspheres adjuvant sargramostim ( GM-CSF ) . Arm II : Patients receive subcutaneous vaccination HER-2 derive p369-377 peptide incorporate PLG microspheres adjuvant GM-CSF . Arm III : Patients receive high dose subcutaneous vaccination HER-2 derive p369-377 peptide incorporate PLG microspheres adjuvant GM-CSF . Treatment repeat every 4 week 6 course absence unacceptable toxicity . PROJECTED ACCRUAL : A total 15 patient ( 5 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Stage III adenocarcinoma overexpresses HER2 previously treat surgical resection , conventional chemotherapy , radiotherapy OR Stage IV adenocarcinoma overexpresses HER2 stable complete remission concurrent chemotherapy Must document HER2 protein overexpression primary metastatic tumor HLAA2 positive PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 90100 % Life expectancy : At least 12 month Hematopoietic : WBC great 3,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 60 mL/min Other : Female patient must complete childbearing Fertile male patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior cytotoxic chemotherapy Endocrine therapy : At least 4 week since prior corticosteroid Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics Other : No concurrent investigational phase I study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage III non-small cell lung cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
</DOC>